FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: ***Telescope Innovations Corp.*** (the "Issuer").

Trading Symbol: ***TELI***

Number of Outstanding Listed Securities: ***80,805,298 common shares***

Date: ***April 7, 2026***

Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

(a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.

(b) The term "Issuer" includes the Issuer and any of its subsidiaries.

(c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer is a developer of intelligent automation and advanced chemical manufacturing technologies. The Issuer builds and deploys enabling technologies including flexible robotic platforms and artificial intelligence

software that improves experimental throughput, efficiency, and data quality. The issuer's "Self-Driving Labs" are fully autonomous, physical AI platforms that plan, execute, and analyze experiments far more efficiently than traditional manual approaches. Bio-pharmaceutical, high value specialty chemical, and advanced materials companies utilize the Issuer's products and services to accelerate the development and optimization of chemical processes, thereby cutting down time and costs from lab to market.

2. Provide a general overview and discussion of the activities of management.

The Issuer rescoped its digital marketing agreement dated September 19, 2025, with Gold Standard Media, LLC ("GSM") and its affiliates and received a refund of $300,000 in previously paid fees so that it is able to use an additional marketing vehicle to support its Investor Marketing activities.

The Issuer engaged Curzio Research Holdings, LLC ("Curzio") for a three month term to provide the Issuer with marketing services, including digital marketing, targeted media relations, ongoing market awareness and strategic council to the Company (the "Curzio Services"). In consideration for the Curzio Services, Curzio will receive an aggregate upfront payment of USD$300,000.

The Issuer signed a Development and Collaboration Agreement (the "Agreement") with AGI Group's Synthesis, Digitization, and Automation program ("AGI SDA"). AGI SDA is an innovator in automated laboratory and pilot plant reactors and related control instrumentation.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer engaged Curzio Research Holdings, LLC to provide marketing services to the Issuer. In consideration for the Curzio Services, Curzio received an aggregate upfront payment of USD$300,000. The Curzio marketing and consulting agreement has a three-month term, which commenced on March 1, 2026, unless terminated earlier in accordance with the terms of the Agreement.

Curzio and its principal and Chief Executive Officer, Frank Curzio, are at arm's length to the Issuer and have advised they do not own any securities in the Issuer.

The Issuer signed a Development and Collaboration Agreement with AGI Group's Synthesis, Digitization, and Automation program ("AGI SDA"). AGI SDA is an innovator in automated laboratory and pilot plant reactors and related control instrumentation.

The partners aim to develop the next generation of automation- and AI-ready chemical reactor technology. This collaboration spearheads a broader effort involving 6 major Bio-Pharmaceutical companies focused on developing such technology, with the intent of ultimately offering an integrated commercial product. The proposed technology would leverage the Issuer's market-proven expertise in capturing high quality and representative samples from chemical reactions and automatically transferring them to downstream instruments for analysis.

This expertise is evidenced by the commercial success of its flagship product, DirectInject-LC™. The Issuer's technology, for reliably managing reaction samples, will be seamlessly integrated into the AGI reactor system, coupling automated reaction execution with real-time, hands-free analysis.

This partnership with AGI strengthens the Issuer's position as the market leader for automating the sampling and analysis of chemical reactions and provides a significant commercial opportunity for both companies.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

   The Issuer rescoped its previously announced digital marketing agreement dated September 19, 2025, with GSM and its affiliates. In connection with the reduction in scope, GSM refunded the Issuer $300,000 in previously paid fees so that the Issuer is able to use an additional marketing vehicle to support its Investor Marketing activities.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable

together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable

8. Describe the acquisition of new customers or loss of customers.

Not applicable

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Dr. Joel M. Hawkins has expanded his consulting role with the Issuer. Dr. Hawkins is an industry-wide authority in automating complex chemistry workflows and enabling the high-value kinetic and mechanistic datasets needed for chemical process development. His expertise will now support the Issuer's expanding work in automated chemistry sampling technologies and autonomous, Self-Driving Laboratories.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable

14. Provide details of any securities issued and options or warrants granted.

Not applicable

15. Provide details of any loans to or by Related Persons.

Not applicable

16. Provide details of any changes in directors, officers or committee members.

Not applicable

17. *Discuss any trends which are likely to impact the* Issuer including trends in the Issuer's market(s) or political/regulatory trends.

No trends impacting during March, 2026

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: March 7, 2026

Henry Dubina
Name of Director or Senior Officer

/s/ "Henry Dubina"
Signature

Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer Telescope Innovations Corp.	For Month Ended March 31, 2026	Date of Report YY/MM/DD 2026/04/07
Issuer Address 301 - 2386 East Mall		
City/Province/Postal Code Vancouver, British Columbia, V6T 1Z3	Issuer Fax No. ( )	Issuer Telephone No. ( )
Contact Name Henry Dubina	Contact Position CEO	Contact Telephone No. 443-994-2182
Contact Email Address henry@telescopeinn.com	Web Site Address telescopeinnovations.com	